Department of Urology, Faculty of Medicine, Universitas Airlangga, Universitas Airlangga Teaching Hospital, Surabaya, East Java, Indonesia.
Int Braz J Urol. 2022 Sep-Oct;48(5):771-781. doi: 10.1590/S1677-5538.IBJU.2022.0119.
Management of Fournier's Gangrene (FG) includes broad-spectrum antibiotics with adequate surgical debridement, which should be performed within the first 24 hours of onset. However, this treatment may cause significant loss of tissue and may delay healing with the presence of ischemia. Hyperbaric oxygen therapy (HBOT) has been proposed as adjunctive therapy to assist the healing process. However, its benefit is still debatable. Therefore, this systematic review and meta-analysis aimed to evaluate the effect of HBOT as an adjunct therapy for FG.
This study complied with the Preferred Reporting Items for Systematic Reviews and Meta-analyses protocol to obtain studies investigating the effect of HBOT on patients with FG. The search is systematically carried out on different databases such as MEDLINE, Embase, and Scopus based on population, intervention, control, and outcomes criteria. A total of 10 articles were retrieved for qualitative and quantitative analysis.
There was a significant difference in mortality as patients with FG who received HBOT had a lower number of deaths compared to patients who received conventional therapy (Odds Ratio 0.29; 95% CI 0.12 - 0.69; p = 0.005). However, the mean length of stay with Mean Difference (MD) of -0.18 (95% CI: -7.68 - 7.33; p=0.96) and the number of debridement procedures (MD 1.33; 95% CI: -0.58 - 3.23; p=0.17) were not significantly different.
HBOT can be used as an adjunct therapy to prevent an increased risk of mortality in patients with FG.
Fournier 坏疽(FG)的治疗包括使用广谱抗生素和充分的手术清创,应在发病后 24 小时内进行。然而,这种治疗可能会导致大量组织损失,并可能因缺血而延迟愈合。高压氧治疗(HBOT)已被提议作为辅助治疗以帮助愈合过程。然而,其益处仍存在争议。因此,本系统评价和荟萃分析旨在评估 HBOT 作为 FG 辅助治疗的效果。
本研究符合系统评价和荟萃分析的首选报告项目协议,以获取研究高压氧对 FG 患者影响的研究。根据人群、干预、对照和结局标准,在 MEDLINE、Embase 和 Scopus 等不同数据库中进行系统搜索。共检索到 10 篇文章进行定性和定量分析。
接受 HBOT 的 FG 患者死亡率存在显著差异,与接受常规治疗的患者相比,死亡率较低(优势比 0.29;95%置信区间 0.12-0.69;p=0.005)。然而,平均住院时间(MD 为-0.18;95%置信区间:-7.68-7.33;p=0.96)和清创次数(MD 为 1.33;95%置信区间:-0.58-3.23;p=0.17)无显著差异。
HBOT 可作为 FG 患者的辅助治疗,以降低死亡率增加的风险。